

Remarks

In the Office Action mailed on June 6, 2007, the examiner divided the claims into the following six groups.

Group I: claims 12-19, drawn to a composition;

Group II: claims 23-28, drawn to a method for detecting the presence of a cell;

Group III: claim 29, drawn to a method for treating pancreatic damage;

Group IV: claim 30, drawn to a method for stimulating regulation of islet cells;

Group V: claim 31, drawn to a method for stimulating insulin cells; and

Group VI: claims 32-40, drawn to a method for treating hyperglycemia.

Applicants elect Group III, including claims 29 and 33-41 as amended without traverse.

Amendments to the Claims

Claims 33, 36, 37, 39, and 40 were amended to depend from claim 29. Claims 1-28 and 30-32 are cancelled without prejudice or disclaimer. Claim 41 was added. Basis for claim 41 is found in the specification as originally filed, for example at page 2, lines 15-22; page 3, lines 10-12 and 27-30; and page 12, lines 16-19. New claim 41 falls into elected Group III because hyperglycemia is a subset of pancreatic damage.

U.S.S.N. 10/523,357
Filed: January 28, 2005

AMENDMENT AND RESPONSE TO OFFICE ACTION

Allowance of claims 29 and 33-41 is respectfully solicited.

Respectfully submitted,

/Patrea L. Pabst/

Patrea L. Pabst

Reg. No. 31,284

Date: December 5, 2007

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2151
(404) 879-2160 (Facsimile)